Form 4: 4D Molecular Therapeutics Officer Sells Shares
Insider Transaction Report
4D Molecular Therapeutics' Chief Legal Officer, Scott Bizily, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged trading plan.
Summary
- Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc. (FDMT), reported transactions on October 16, 2025.
- Bizily exercised stock options to acquire 1,635 shares of common stock at an exercise price of $4.14 per share.
- Concurrently, he sold 1,635 shares of common stock at a price of $10.17 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on June 6, 2025.
- Following these transactions, Bizily directly holds 5,188 shares of common stock and 76,865 stock options.
Sentiment
Score: 5
Explanation: The filing reports a routine insider transaction under a pre-arranged 10b5-1 plan, which is generally considered neutral. While the officer profited from the sale, it's a planned event rather than an opportunistic one, balancing potential negative perceptions of insider selling.
Positives
- The sale price of $10.17 per share is significantly higher than the exercise price of $4.14 per share, indicating a profitable transaction for the reporting person.
- The transactions were conducted under a pre-arranged 10b5-1 trading plan, which suggests a systematic approach to managing equity holdings rather than opportunistic trading.
Negatives
- The sale of shares by a Chief Legal Officer could be interpreted by some investors as a lack of confidence, although it is a common practice for personal financial planning, especially when executed under a 10b5-1 plan.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing reports a routine insider transaction under a pre-arranged trading plan, which is a common practice across industries for executives to manage their equity compensation and personal finances. It does not provide specific insights into broader industry trends or competitive positioning.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Adoption | The reporting person adopted a Rule 10b5-1 trading plan on June 6, 2025, under which the reported transactions were executed. This plan allows insiders to pre-arrange trades to avoid accusations of insider trading. | 06/06/2025 | Enhances transparency and provides an affirmative defense against insider trading allegations for pre-scheduled transactions. |
Stakeholder Impact
- Shareholders: The transaction represents a routine insider sale, which may be viewed neutrally or with slight caution depending on individual investor sentiment towards insider selling, even under a 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | Vesting Commencement Date for stock options, with 1/48th of shares vesting monthly. |
| 06/06/2025 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 10/16/2025 | Date of the reported stock option exercise and subsequent sale of common stock. |
| 10/20/2025 | Date the Form 4 filing was signed by the reporting person. |
| 03/05/2035 | Expiration Date of the stock options. |
Keywords
FDMT, 4D Molecular Therapeutics, Scott Bizily, Insider Trading, Stock Option Exercise, 10b5-1 Plan, Common Stock Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.